Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Background Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-modified T cells targeting both CD19 and CD22 may overcome the limitation of CD19...
Uloženo v:
| Vydáno v: | Journal of hematology and oncology Ročník 13; číslo 1; s. 30 - 10 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
BioMed Central
03.04.2020
BioMed Central Ltd Springer Nature B.V BMC |
| Témata: | |
| ISSN: | 1756-8722, 1756-8722 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background
Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-modified T cells targeting both CD19 and CD22 may overcome the limitation of CD19-negative relapse.
Methods
We here report the design of a bispecific CAR simultaneous targeting of CD19 and CD22. We performed a phase 1 trial of bispecific CAR T cell therapy in patients with relapsed/refractory precursor B-ALL at a dose that ranged from 1.7 × 10
6
to 3 × 10
6
CAR T cells per kilogram of body weight.
Results
We demonstrate bispecific CD19/CD22 CAR T cells could trigger robust cytolytic activity against target cells. MRD-negative CR was achieved in 6 out of 6 enrolled patients. Autologous CD19/CD22 CAR T cells proliferated in vivo and were detected in the blood, bone marrow, and cerebrospinal fluid. No neurotoxicity occurred in any of the 6 patients treated. Of note, one patient had a relapse with blast cells that no longer expressed CD19 and exhibited diminished CD22 site density approximately 5 months after treatment.
Conclusion
In brief, autologous CD19/CD22 CAR T cell therapy is feasible and safe and mediates potent anti-leukemic activity in patients with relapsed/refractory B-ALL. Furthermore, the emergence of target antigen loss and expression downregulation highlights the critical need to anticipate antigen escape. Our study demonstrates the reliability of bispecific CD19/CD22 CAR T cell therapy in inducing remission in adult patients with relapsed/refractory B-ALL.
Trial registration
ClinicalTrials.gov identifier:
NCT03185494
. |
|---|---|
| AbstractList | Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-modified T cells targeting both CD19 and CD22 may overcome the limitation of CD19-negative relapse.
We here report the design of a bispecific CAR simultaneous targeting of CD19 and CD22. We performed a phase 1 trial of bispecific CAR T cell therapy in patients with relapsed/refractory precursor B-ALL at a dose that ranged from 1.7 × 10
to 3 × 10
CAR T cells per kilogram of body weight.
We demonstrate bispecific CD19/CD22 CAR T cells could trigger robust cytolytic activity against target cells. MRD-negative CR was achieved in 6 out of 6 enrolled patients. Autologous CD19/CD22 CAR T cells proliferated in vivo and were detected in the blood, bone marrow, and cerebrospinal fluid. No neurotoxicity occurred in any of the 6 patients treated. Of note, one patient had a relapse with blast cells that no longer expressed CD19 and exhibited diminished CD22 site density approximately 5 months after treatment.
In brief, autologous CD19/CD22 CAR T cell therapy is feasible and safe and mediates potent anti-leukemic activity in patients with relapsed/refractory B-ALL. Furthermore, the emergence of target antigen loss and expression downregulation highlights the critical need to anticipate antigen escape. Our study demonstrates the reliability of bispecific CD19/CD22 CAR T cell therapy in inducing remission in adult patients with relapsed/refractory B-ALL.
ClinicalTrials.gov identifier: NCT03185494. Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-modified T cells targeting both CD19 and CD22 may overcome the limitation of CD19-negative relapse.BACKGROUNDDespite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-modified T cells targeting both CD19 and CD22 may overcome the limitation of CD19-negative relapse.We here report the design of a bispecific CAR simultaneous targeting of CD19 and CD22. We performed a phase 1 trial of bispecific CAR T cell therapy in patients with relapsed/refractory precursor B-ALL at a dose that ranged from 1.7 × 106 to 3 × 106 CAR T cells per kilogram of body weight.METHODSWe here report the design of a bispecific CAR simultaneous targeting of CD19 and CD22. We performed a phase 1 trial of bispecific CAR T cell therapy in patients with relapsed/refractory precursor B-ALL at a dose that ranged from 1.7 × 106 to 3 × 106 CAR T cells per kilogram of body weight.We demonstrate bispecific CD19/CD22 CAR T cells could trigger robust cytolytic activity against target cells. MRD-negative CR was achieved in 6 out of 6 enrolled patients. Autologous CD19/CD22 CAR T cells proliferated in vivo and were detected in the blood, bone marrow, and cerebrospinal fluid. No neurotoxicity occurred in any of the 6 patients treated. Of note, one patient had a relapse with blast cells that no longer expressed CD19 and exhibited diminished CD22 site density approximately 5 months after treatment.RESULTSWe demonstrate bispecific CD19/CD22 CAR T cells could trigger robust cytolytic activity against target cells. MRD-negative CR was achieved in 6 out of 6 enrolled patients. Autologous CD19/CD22 CAR T cells proliferated in vivo and were detected in the blood, bone marrow, and cerebrospinal fluid. No neurotoxicity occurred in any of the 6 patients treated. Of note, one patient had a relapse with blast cells that no longer expressed CD19 and exhibited diminished CD22 site density approximately 5 months after treatment.In brief, autologous CD19/CD22 CAR T cell therapy is feasible and safe and mediates potent anti-leukemic activity in patients with relapsed/refractory B-ALL. Furthermore, the emergence of target antigen loss and expression downregulation highlights the critical need to anticipate antigen escape. Our study demonstrates the reliability of bispecific CD19/CD22 CAR T cell therapy in inducing remission in adult patients with relapsed/refractory B-ALL.CONCLUSIONIn brief, autologous CD19/CD22 CAR T cell therapy is feasible and safe and mediates potent anti-leukemic activity in patients with relapsed/refractory B-ALL. Furthermore, the emergence of target antigen loss and expression downregulation highlights the critical need to anticipate antigen escape. Our study demonstrates the reliability of bispecific CD19/CD22 CAR T cell therapy in inducing remission in adult patients with relapsed/refractory B-ALL.ClinicalTrials.gov identifier: NCT03185494.TRIAL REGISTRATIONClinicalTrials.gov identifier: NCT03185494. Background Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-modified T cells targeting both CD19 and CD22 may overcome the limitation of CD19-negative relapse. Methods We here report the design of a bispecific CAR simultaneous targeting of CD19 and CD22. We performed a phase 1 trial of bispecific CAR T cell therapy in patients with relapsed/refractory precursor B-ALL at a dose that ranged from 1.7 × 106 to 3 × 106 CAR T cells per kilogram of body weight. Results We demonstrate bispecific CD19/CD22 CAR T cells could trigger robust cytolytic activity against target cells. MRD-negative CR was achieved in 6 out of 6 enrolled patients. Autologous CD19/CD22 CAR T cells proliferated in vivo and were detected in the blood, bone marrow, and cerebrospinal fluid. No neurotoxicity occurred in any of the 6 patients treated. Of note, one patient had a relapse with blast cells that no longer expressed CD19 and exhibited diminished CD22 site density approximately 5 months after treatment. Conclusion In brief, autologous CD19/CD22 CAR T cell therapy is feasible and safe and mediates potent anti-leukemic activity in patients with relapsed/refractory B-ALL. Furthermore, the emergence of target antigen loss and expression downregulation highlights the critical need to anticipate antigen escape. Our study demonstrates the reliability of bispecific CD19/CD22 CAR T cell therapy in inducing remission in adult patients with relapsed/refractory B-ALL. Trial registration ClinicalTrials.gov identifier: NCT03185494. Abstract Background Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-modified T cells targeting both CD19 and CD22 may overcome the limitation of CD19-negative relapse. Methods We here report the design of a bispecific CAR simultaneous targeting of CD19 and CD22. We performed a phase 1 trial of bispecific CAR T cell therapy in patients with relapsed/refractory precursor B-ALL at a dose that ranged from 1.7 × 106 to 3 × 106 CAR T cells per kilogram of body weight. Results We demonstrate bispecific CD19/CD22 CAR T cells could trigger robust cytolytic activity against target cells. MRD-negative CR was achieved in 6 out of 6 enrolled patients. Autologous CD19/CD22 CAR T cells proliferated in vivo and were detected in the blood, bone marrow, and cerebrospinal fluid. No neurotoxicity occurred in any of the 6 patients treated. Of note, one patient had a relapse with blast cells that no longer expressed CD19 and exhibited diminished CD22 site density approximately 5 months after treatment. Conclusion In brief, autologous CD19/CD22 CAR T cell therapy is feasible and safe and mediates potent anti-leukemic activity in patients with relapsed/refractory B-ALL. Furthermore, the emergence of target antigen loss and expression downregulation highlights the critical need to anticipate antigen escape. Our study demonstrates the reliability of bispecific CD19/CD22 CAR T cell therapy in inducing remission in adult patients with relapsed/refractory B-ALL. Trial registration ClinicalTrials.gov identifier: NCT03185494 . Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-modified T cells targeting both CD19 and CD22 may overcome the limitation of CD19-negative relapse. We here report the design of a bispecific CAR simultaneous targeting of CD19 and CD22. We performed a phase 1 trial of bispecific CAR T cell therapy in patients with relapsed/refractory precursor B-ALL at a dose that ranged from 1.7 x 10.sup.6 to 3 x 10.sup.6 CAR T cells per kilogram of body weight. We demonstrate bispecific CD19/CD22 CAR T cells could trigger robust cytolytic activity against target cells. MRD-negative CR was achieved in 6 out of 6 enrolled patients. Autologous CD19/CD22 CAR T cells proliferated in vivo and were detected in the blood, bone marrow, and cerebrospinal fluid. No neurotoxicity occurred in any of the 6 patients treated. Of note, one patient had a relapse with blast cells that no longer expressed CD19 and exhibited diminished CD22 site density approximately 5 months after treatment. In brief, autologous CD19/CD22 CAR T cell therapy is feasible and safe and mediates potent anti-leukemic activity in patients with relapsed/refractory B-ALL. Furthermore, the emergence of target antigen loss and expression downregulation highlights the critical need to anticipate antigen escape. Our study demonstrates the reliability of bispecific CD19/CD22 CAR T cell therapy in inducing remission in adult patients with relapsed/refractory B-ALL. Background Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-modified T cells targeting both CD19 and CD22 may overcome the limitation of CD19-negative relapse. Methods We here report the design of a bispecific CAR simultaneous targeting of CD19 and CD22. We performed a phase 1 trial of bispecific CAR T cell therapy in patients with relapsed/refractory precursor B-ALL at a dose that ranged from 1.7 x 10.sup.6 to 3 x 10.sup.6 CAR T cells per kilogram of body weight. Results We demonstrate bispecific CD19/CD22 CAR T cells could trigger robust cytolytic activity against target cells. MRD-negative CR was achieved in 6 out of 6 enrolled patients. Autologous CD19/CD22 CAR T cells proliferated in vivo and were detected in the blood, bone marrow, and cerebrospinal fluid. No neurotoxicity occurred in any of the 6 patients treated. Of note, one patient had a relapse with blast cells that no longer expressed CD19 and exhibited diminished CD22 site density approximately 5 months after treatment. Conclusion In brief, autologous CD19/CD22 CAR T cell therapy is feasible and safe and mediates potent anti-leukemic activity in patients with relapsed/refractory B-ALL. Furthermore, the emergence of target antigen loss and expression downregulation highlights the critical need to anticipate antigen escape. Our study demonstrates the reliability of bispecific CD19/CD22 CAR T cell therapy in inducing remission in adult patients with relapsed/refractory B-ALL. Trial registration ClinicalTrials.gov identifier: NCT03185494. Keywords: Bispecific, CAR, CD19, CD22, B-ALL, Immunotherapy, Tumor antigen escape Background Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-modified T cells targeting both CD19 and CD22 may overcome the limitation of CD19-negative relapse. Methods We here report the design of a bispecific CAR simultaneous targeting of CD19 and CD22. We performed a phase 1 trial of bispecific CAR T cell therapy in patients with relapsed/refractory precursor B-ALL at a dose that ranged from 1.7 × 10 6 to 3 × 10 6 CAR T cells per kilogram of body weight. Results We demonstrate bispecific CD19/CD22 CAR T cells could trigger robust cytolytic activity against target cells. MRD-negative CR was achieved in 6 out of 6 enrolled patients. Autologous CD19/CD22 CAR T cells proliferated in vivo and were detected in the blood, bone marrow, and cerebrospinal fluid. No neurotoxicity occurred in any of the 6 patients treated. Of note, one patient had a relapse with blast cells that no longer expressed CD19 and exhibited diminished CD22 site density approximately 5 months after treatment. Conclusion In brief, autologous CD19/CD22 CAR T cell therapy is feasible and safe and mediates potent anti-leukemic activity in patients with relapsed/refractory B-ALL. Furthermore, the emergence of target antigen loss and expression downregulation highlights the critical need to anticipate antigen escape. Our study demonstrates the reliability of bispecific CD19/CD22 CAR T cell therapy in inducing remission in adult patients with relapsed/refractory B-ALL. Trial registration ClinicalTrials.gov identifier: NCT03185494 . |
| ArticleNumber | 30 |
| Audience | Academic |
| Author | Dai, Hanren Wu, Zhiqiang Tong, Chuan Guo, Yelei Han, Xiao Chen, Meixia Ti, Dongdong Liu, Yang Wang, Chunmeng Jia, Hejin Wang, Yao Zhang, Wenying Yang, Qingming Han, Weidong Zhang, Yajing |
| Author_xml | – sequence: 1 givenname: Hanren surname: Dai fullname: Dai, Hanren organization: Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese PLA General Hospital, Department of Bio-therapeutic, Chinese PLA General Hospital, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University – sequence: 2 givenname: Zhiqiang surname: Wu fullname: Wu, Zhiqiang organization: Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese PLA General Hospital – sequence: 3 givenname: Hejin surname: Jia fullname: Jia, Hejin organization: Department of Bio-therapeutic, Chinese PLA General Hospital – sequence: 4 givenname: Chuan surname: Tong fullname: Tong, Chuan organization: Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese PLA General Hospital – sequence: 5 givenname: Yelei surname: Guo fullname: Guo, Yelei organization: Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese PLA General Hospital – sequence: 6 givenname: Dongdong surname: Ti fullname: Ti, Dongdong organization: Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese PLA General Hospital – sequence: 7 givenname: Xiao surname: Han fullname: Han, Xiao organization: Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese PLA General Hospital – sequence: 8 givenname: Yang surname: Liu fullname: Liu, Yang organization: Department of Geriatric Hematology, Chinese PLA General Hospital – sequence: 9 givenname: Wenying surname: Zhang fullname: Zhang, Wenying organization: Department of Bio-therapeutic, Chinese PLA General Hospital – sequence: 10 givenname: Chunmeng surname: Wang fullname: Wang, Chunmeng organization: Department of Bio-therapeutic, Chinese PLA General Hospital – sequence: 11 givenname: Yajing surname: Zhang fullname: Zhang, Yajing organization: Department of Bio-therapeutic, Chinese PLA General Hospital – sequence: 12 givenname: Meixia surname: Chen fullname: Chen, Meixia organization: Department of Bio-therapeutic, Chinese PLA General Hospital – sequence: 13 givenname: Qingming surname: Yang fullname: Yang, Qingming organization: Department of Bio-therapeutic, Chinese PLA General Hospital – sequence: 14 givenname: Yao surname: Wang fullname: Wang, Yao email: wangyao301@163.com organization: Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese PLA General Hospital – sequence: 15 givenname: Weidong surname: Han fullname: Han, Weidong email: hanwdrsw69@yahoo.com, hanwdrsw@sina.com organization: Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese PLA General Hospital, Department of Bio-therapeutic, Chinese PLA General Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32245502$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kluL1DAcxYusuBf9Aj5IQBBfuubSS_oizI63hQVB1ueQJv-2WTPNmKTKfAS_tenMrjuzyFJCQ_o7J8npOc2ORjdClr0k-JwQXr0LhOGizDHFOca8rHL-JDsh9TypKT3amx9npyHcYFyRhuJn2TGjtChLTE-yPxcmrEGZzii0XHzLr5ECawOK0vcQzdij1sUBLT-QBslRpwmlqHMexQG8XG-Q65DUk40B_TYJ9GDlOoBGCfHQeami8xt0sbVFUk0RkN2s1oNrrQwx7Wph-gErI59nTztpA7y4fZ9l3z99vF5-ya--fr5cLq5yVTEec8paXJctbjjueAOKceg4YbycR6GZxoQ2TFUYeFkXNe5kg0lbaUUZ5ZpqdpZd7ny1kzdi7c1K-o1w0ojtgvO9kD4dzIIoNVVt12jAuCzqpuWyaLEuFC9kQaHiyev9zms9tSvQCsbopT0wPfwymkH07peoCa1YUySDt7cG3v2cIESxMmGOSo7gpiAo4xWt02gS-voBeuMmP6aoEtUQypuS4nuql-kCZuxc2lfNpmKRnBitOK8Sdf4fKj06_QmVWtaZtH4geLMnGEDaOARnp2jcGA7BV_uJ_IvirnEJ4DtAeRdCqohQJsrZJx3BWEGwmMstduUWqdxiW24xp00fSO_cHxWxnSgkeOzB38f2iOoveMAIcQ |
| CitedBy_id | crossref_primary_10_1016_j_tranon_2025_102425 crossref_primary_10_1111_bjh_19348 crossref_primary_10_3390_ijms25147743 crossref_primary_10_1080_10428194_2021_1980214 crossref_primary_10_1016_j_biomaterials_2024_122607 crossref_primary_10_1186_s40164_023_00397_z crossref_primary_10_1038_s41467_024_47801_8 crossref_primary_10_1016_j_jgeb_2024_100446 crossref_primary_10_1186_s13045_023_01467_9 crossref_primary_10_3389_fped_2022_923419 crossref_primary_10_1016_j_bulcan_2021_09_002 crossref_primary_10_1186_s40164_024_00561_z crossref_primary_10_1038_s41417_021_00418_1 crossref_primary_10_1016_j_tibtech_2021_09_005 crossref_primary_10_1097_COC_0000000000001176 crossref_primary_10_1016_j_cellsig_2023_110638 crossref_primary_10_1016_j_intimp_2024_113166 crossref_primary_10_1016_j_jcyt_2021_02_117 crossref_primary_10_1186_s12967_025_06567_3 crossref_primary_10_1038_s41392_023_01659_2 crossref_primary_10_1016_j_ymthe_2025_08_002 crossref_primary_10_3389_fimmu_2022_927153 crossref_primary_10_3389_fonc_2022_1082235 crossref_primary_10_1016_j_cell_2025_07_046 crossref_primary_10_1038_s41467_024_54150_z crossref_primary_10_1016_j_jbc_2021_100966 crossref_primary_10_1080_21645515_2024_2371664 crossref_primary_10_1007_s10147_023_02346_6 crossref_primary_10_3389_fimmu_2023_1178403 crossref_primary_10_1182_bloodadvances_2024013586 crossref_primary_10_1016_j_omto_2021_08_005 crossref_primary_10_1186_s40364_021_00316_6 crossref_primary_10_1097_CM9_0000000000002476 crossref_primary_10_1186_s12967_024_05206_7 crossref_primary_10_1177_15330338231204198 crossref_primary_10_3390_cancers13050981 crossref_primary_10_3389_fimmu_2022_808347 crossref_primary_10_1186_s40364_022_00434_9 crossref_primary_10_3390_ijms22042150 crossref_primary_10_1186_s40164_022_00316_8 crossref_primary_10_1002_anie_202113341 crossref_primary_10_1016_j_bulcan_2022_04_017 crossref_primary_10_1038_s41392_022_00915_1 crossref_primary_10_3892_mco_2022_2567 crossref_primary_10_3390_genes14051008 crossref_primary_10_1186_s40164_022_00270_5 crossref_primary_10_1080_07853890_2024_2349796 crossref_primary_10_3389_fimmu_2025_1567149 crossref_primary_10_1016_j_bbcan_2025_189277 crossref_primary_10_3390_biomedicines11102693 crossref_primary_10_3390_cancers12092523 crossref_primary_10_1038_s41571_022_00607_3 crossref_primary_10_1021_acsnano_5c07896 crossref_primary_10_1038_s41408_021_00459_7 crossref_primary_10_1182_blood_2023020621 crossref_primary_10_1007_s12185_021_03085_y crossref_primary_10_1177_10815589231191811 crossref_primary_10_1038_s41375_021_01345_8 crossref_primary_10_1038_s41392_022_00898_z crossref_primary_10_1182_bloodadvances_2020003482 crossref_primary_10_3390_ijms26178662 crossref_primary_10_1038_s41591_021_01436_0 crossref_primary_10_1136_jitc_2022_005054 crossref_primary_10_2147_ITT_S288546 crossref_primary_10_1111_ejh_14074 crossref_primary_10_3389_fped_2021_784024 crossref_primary_10_1038_s41408_024_01105_8 crossref_primary_10_3389_fneur_2024_1437778 crossref_primary_10_1111_jcmm_16939 crossref_primary_10_3390_ijms252212201 crossref_primary_10_1080_10428194_2021_1894648 crossref_primary_10_3390_cancers14040967 crossref_primary_10_3389_fimmu_2022_1066748 crossref_primary_10_1053_j_seminhematol_2023_03_001 crossref_primary_10_1155_2022_1227308 crossref_primary_10_1186_s40164_023_00454_7 crossref_primary_10_3892_ol_2022_13478 crossref_primary_10_1016_j_ymthe_2021_08_033 crossref_primary_10_3389_fonc_2024_1396395 crossref_primary_10_3389_fonc_2024_1399544 crossref_primary_10_3390_ijms25073780 crossref_primary_10_1186_s40364_021_00294_9 crossref_primary_10_3389_fimmu_2022_921894 crossref_primary_10_3390_biomedicines11071886 crossref_primary_10_1007_s43152_025_00064_x crossref_primary_10_1182_bloodadvances_2022009462 crossref_primary_10_1016_j_tranon_2021_101079 crossref_primary_10_1007_s12015_021_10246_3 crossref_primary_10_3389_fimmu_2021_609421 crossref_primary_10_1111_ejh_14090 crossref_primary_10_1053_j_seminhematol_2020_08_001 crossref_primary_10_1002_imed_1037 crossref_primary_10_3892_mco_2023_2691 crossref_primary_10_1186_s13045_020_00910_5 crossref_primary_10_1038_s41598_022_06830_3 crossref_primary_10_1186_s13045_020_00934_x crossref_primary_10_1016_j_coisb_2021_100371 crossref_primary_10_1111_bjh_19631 crossref_primary_10_3389_fcell_2022_969020 crossref_primary_10_3390_cancers17142300 crossref_primary_10_1186_s40164_022_00291_0 crossref_primary_10_1038_s41392_024_01856_7 crossref_primary_10_1080_10428194_2023_2232496 crossref_primary_10_1080_2162402X_2020_1777064 crossref_primary_10_1158_2326_6066_CIR_22_0366 crossref_primary_10_1158_1078_0432_CCR_20_3863 crossref_primary_10_2147_CMAR_S521944 crossref_primary_10_1016_j_tranon_2022_101575 crossref_primary_10_1186_s12935_025_03697_y crossref_primary_10_3390_cells10061511 crossref_primary_10_1021_acsnano_4c05065 crossref_primary_10_1186_s13045_021_01077_3 crossref_primary_10_1155_jimr_5845167 crossref_primary_10_3390_biomedicines10071493 crossref_primary_10_1515_hsz_2023_0329 crossref_primary_10_1007_s11684_021_0901_2 crossref_primary_10_1016_j_jtct_2024_11_012 crossref_primary_10_1016_j_addr_2022_114301 crossref_primary_10_3389_fimmu_2023_1166038 crossref_primary_10_1631_jzus_B2200256 crossref_primary_10_3390_biom12091239 crossref_primary_10_1177_15330338221118413 crossref_primary_10_3389_fimmu_2021_627764 crossref_primary_10_1186_s12943_022_01669_8 crossref_primary_10_3390_ijms26073206 crossref_primary_10_1016_j_tranon_2022_101342 crossref_primary_10_1002_advs_202305566 crossref_primary_10_2147_OTT_S312904 crossref_primary_10_3390_cancers16071334 crossref_primary_10_3390_cells13181596 crossref_primary_10_1002_ange_202113341 crossref_primary_10_3389_fonc_2024_1434495 crossref_primary_10_2147_BTT_S252568 crossref_primary_10_3389_fimmu_2023_1121030 crossref_primary_10_3390_ijms222111694 crossref_primary_10_1186_s12967_023_04019_4 crossref_primary_10_1186_s13643_021_01588_7 crossref_primary_10_1016_j_ymthe_2020_10_023 crossref_primary_10_1002_smll_202401299 crossref_primary_10_1016_j_hoc_2023_06_003 crossref_primary_10_1186_s13045_020_00878_2 crossref_primary_10_1002_smtd_202100071 crossref_primary_10_3390_cells10112845 crossref_primary_10_1038_s41467_024_44885_0 crossref_primary_10_1007_s12185_022_03436_3 crossref_primary_10_3389_fimmu_2025_1574742 crossref_primary_10_1007_s00262_022_03163_y crossref_primary_10_3390_ph14100993 crossref_primary_10_1097_MOH_0000000000000892 crossref_primary_10_1016_j_jtct_2022_06_001 crossref_primary_10_1016_j_copbio_2021_07_007 crossref_primary_10_3389_fimmu_2023_1165870 crossref_primary_10_1002_mco2_155 crossref_primary_10_3390_cancers15112881 crossref_primary_10_1097_JS9_0000000000002111 crossref_primary_10_1016_j_ijid_2024_107043 crossref_primary_10_1111_cas_14799 crossref_primary_10_3390_cancers15133346 crossref_primary_10_1007_s11684_021_0904_z crossref_primary_10_1016_j_medj_2022_05_001 crossref_primary_10_2217_imt_2021_0065 crossref_primary_10_3390_jcm12216883 crossref_primary_10_3389_fmed_2025_1544025 crossref_primary_10_3390_ph17121629 crossref_primary_10_1016_j_beha_2021_101277 crossref_primary_10_3389_fimmu_2025_1557405 crossref_primary_10_1080_10428194_2022_2115841 crossref_primary_10_1182_bloodadvances_2022008559 crossref_primary_10_1111_ejh_14101 crossref_primary_10_1016_j_jsbmb_2024_106571 crossref_primary_10_1158_2326_6066_CIR_20_0675 crossref_primary_10_1097_BS9_0000000000000184 crossref_primary_10_1038_s41423_021_00732_6 crossref_primary_10_3390_cancers16010039 crossref_primary_10_1186_s40164_024_00593_5 crossref_primary_10_1016_j_yexcr_2021_112971 crossref_primary_10_4103_jcrt_jcrt_976_21 crossref_primary_10_3389_fonc_2022_954345 crossref_primary_10_1038_s41408_023_00819_5 crossref_primary_10_1002_ajh_27076 crossref_primary_10_1080_14712598_2022_2086043 crossref_primary_10_3389_fimmu_2024_1414264 crossref_primary_10_1007_s11864_023_01140_w crossref_primary_10_1186_s12943_023_01720_2 crossref_primary_10_1016_j_jconrel_2023_04_048 crossref_primary_10_3389_fimmu_2020_569117 crossref_primary_10_1089_hum_2022_183 crossref_primary_10_3390_ph15020207 crossref_primary_10_1016_j_omto_2022_02_012 crossref_primary_10_1038_s41598_022_16616_2 crossref_primary_10_1016_j_leukres_2024_107569 crossref_primary_10_1186_s13045_020_00998_9 crossref_primary_10_1016_j_jmr_2022_107234 crossref_primary_10_3390_biomedicines10092286 crossref_primary_10_1182_blood_2022015795 crossref_primary_10_3389_fphar_2022_1041073 crossref_primary_10_3389_fimmu_2022_961805 crossref_primary_10_3389_fimmu_2024_1459818 crossref_primary_10_1186_s40164_024_00570_y crossref_primary_10_3390_biomedicines10020381 crossref_primary_10_1016_j_bbrc_2022_01_070 crossref_primary_10_1126_scitranslmed_abm1262 crossref_primary_10_3389_fonc_2021_627549 crossref_primary_10_3390_cancers14133230 |
| Cites_doi | 10.1126/scitranslmed.aaf8621 10.1038/leu.2017.145 10.1038/s41591-018-0146-z 10.1111/bjh.13562 10.1126/scitranslmed.3008226 10.1038/s41586-019-1054-1 10.1016/S0140-6736(14)61403-3 10.1038/s41591-018-0041-7 10.1080/2162402X.2015.1027469 10.1182/blood-2016-04-703751 10.1056/NEJMoa1709919 10.1038/mt.2013.185 10.1038/nrc3581 10.1182/blood-2013-02-485623 10.1093/neuonc/nox182 10.1016/j.omto.2018.10.006 10.1182/blood-2014-05-552729 10.1182/blood-2015-03-580027 10.1016/j.bbmt.2018.12.758 10.1158/2159-8290.CD-15-1020 10.1158/2326-6066.CIR-15-0231 10.1200/JCO.2014.56.2025 10.1126/scitranslmed.3002842 10.1158/2159-8290.CD-18-0442 10.1093/jnci/djv439 10.1182/blood-2011-12-399287 10.1038/s41591-018-0036-4 10.3324/haematol.2017.183459 10.1038/mtna.2013.32 10.1182/blood-2006-05-018192 10.1158/2326-6066.CIR-13-0006 10.1056/NEJMoa1709866 10.1097/MOP.0b013e32834ec9c1 10.1038/nm.4441 10.1158/2159-8290.CD-16-0040 10.1056/NEJMra1706169 10.1084/jem.20050732 10.1056/NEJMoa1407222 10.1182/blood.2019000017 10.1172/JCI83416 10.1182/blood-2012-08-234492 10.1172/JCI85309 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020 corrected publication. April 2020 COPYRIGHT 2020 BioMed Central Ltd. 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2020 |
| Copyright_xml | – notice: The Author(s) 2020 corrected publication. April 2020 – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2020 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13045-020-00856-8 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1756-8722 |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_5d2cbf9de005479b8a4b0d4c84a42e68 PMC7126394 A627326886 32245502 10_1186_s13045_020_00856_8 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Clinical Trial, Phase I |
| GrantInformation_xml | – fundername: National Key Research and Development Program of China grantid: 2016YFC1303501; 2016YFC1303504 – fundername: National Key Research and Development Program of China grantid: 2017YFC0909803 – fundername: National Natural Science Foundation of China grantid: 31870873 – fundername: National Natural Science Foundation of China grantid: 81830002; 81602711 funderid: http://dx.doi.org/10.13039/501100001809 – fundername: ; grantid: 2017YFC0909803 – fundername: ; grantid: 81830002; 81602711 – fundername: ; grantid: 31870873 – fundername: ; grantid: 2016YFC1303501; 2016YFC1303504 |
| GroupedDBID | --- 0R~ 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP ~8M AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7T5 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c638t-23b075b0980f89ec38ef8138513854d3d01293c60e857470fa901b6dc2328d2d3 |
| IEDL.DBID | 7X7 |
| ISICitedReferencesCount | 239 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000523731800003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1756-8722 |
| IngestDate | Mon Nov 10 04:29:24 EST 2025 Tue Nov 04 02:01:36 EST 2025 Fri Sep 05 07:10:59 EDT 2025 Sun Oct 19 00:03:35 EDT 2025 Tue Nov 11 10:19:18 EST 2025 Tue Nov 04 17:58:32 EST 2025 Thu May 22 21:22:36 EDT 2025 Mon Jul 21 05:31:55 EDT 2025 Sat Nov 29 06:33:48 EST 2025 Tue Nov 18 21:56:36 EST 2025 Sat Sep 06 07:21:53 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | B-ALL CAR Bispecific CD19 Immunotherapy Tumor antigen escape CD22 |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c638t-23b075b0980f89ec38ef8138513854d3d01293c60e857470fa901b6dc2328d2d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/2391289520?pq-origsite=%requestingapplication% |
| PMID | 32245502 |
| PQID | 2391289520 |
| PQPubID | 54946 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_5d2cbf9de005479b8a4b0d4c84a42e68 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7126394 proquest_miscellaneous_2386278629 proquest_journals_2391289520 gale_infotracmisc_A627326886 gale_infotracacademiconefile_A627326886 gale_healthsolutions_A627326886 pubmed_primary_32245502 crossref_citationtrail_10_1186_s13045_020_00856_8 crossref_primary_10_1186_s13045_020_00856_8 springer_journals_10_1186_s13045_020_00856_8 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-04-03 |
| PublicationDateYYYYMMDD | 2020-04-03 |
| PublicationDate_xml | – month: 04 year: 2020 text: 2020-04-03 day: 03 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Journal of hematology and oncology |
| PublicationTitleAbbrev | J Hematol Oncol |
| PublicationTitleAlternate | J Hematol Oncol |
| PublicationYear | 2020 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | H Dai (856_CR7) 2015; 4 T Giavridis (856_CR40) 2018; 24 N Gokbuget (856_CR22) 2012; 120 DT Teachey (856_CR42) 2016; 6 856_CR1 ML Davila (856_CR3) 2014; 6 M Kalos (856_CR23) 2011; 3 856_CR19 DW Lee (856_CR25) 2014; 124 M Norelli (856_CR41) 2018; 24 L Gattinoni (856_CR16) 2005; 202 EJ Orlando (856_CR9) 2018; 24 DW Lee (856_CR26) 2019; 25 N Wang (856_CR36) 2020; 135 DT Teachey (856_CR38) 2013; 121 AK Fielding (856_CR21) 2007; 109 E Zah (856_CR30) 2016; 4 NNS Haneen Shalabi (856_CR32) 2017; 130 M Hegde (856_CR15) 2016; 126 CJ Turtle (856_CR18) 2016; 126 JN Kochenderfer (856_CR24) 2015; 33 DW Lee (856_CR4) 2015; 385 MV Maus (856_CR33) 2013; 1 M Hamieh (856_CR34) 2019; 568 CJ Turtle (856_CR31) 2016; 8 H Shalabi (856_CR35) 2018; 103 E Sotillo (856_CR8) 2015; 5 AG Evans (856_CR10) 2015; 171 K Bielamowicz (856_CR14) 2018; 20 CH June (856_CR2) 2018; 379 J Pan (856_CR37) 2017; 31 TJ Fry (856_CR11) 2018; 24 K Risma (856_CR39) 2012; 24 RG Majzner (856_CR28) 2018; 8 M Hegde (856_CR13) 2013; 21 H Qin (856_CR29) 2018; 11 856_CR6 JE Talmadge (856_CR17) 2013; 13 SL Maude (856_CR5) 2014; 371 856_CR43 Z Grada (856_CR12) 2013; 2 SJ Forman (856_CR27) 2013; 121 856_CR20 32423426 - J Hematol Oncol. 2020 May 18;13(1):53 |
| References_xml | – volume: 8 start-page: 355ra116 issue: 355 year: 2016 ident: 856_CR31 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aaf8621 – volume: 31 start-page: 2587 issue: 12 year: 2017 ident: 856_CR37 publication-title: Leukemia doi: 10.1038/leu.2017.145 – volume: 24 start-page: 1504 issue: 10 year: 2018 ident: 856_CR9 publication-title: Nat Med doi: 10.1038/s41591-018-0146-z – volume: 171 start-page: 205 issue: 2 year: 2015 ident: 856_CR10 publication-title: Br J Haematol doi: 10.1111/bjh.13562 – volume: 6 start-page: 224ra25 issue: 224 year: 2014 ident: 856_CR3 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3008226 – volume: 568 start-page: 112 issue: 7750 year: 2019 ident: 856_CR34 publication-title: Nature doi: 10.1038/s41586-019-1054-1 – volume: 385 start-page: 517 issue: 9967 year: 2015 ident: 856_CR4 publication-title: Lancet doi: 10.1016/S0140-6736(14)61403-3 – volume: 24 start-page: 731 issue: 6 year: 2018 ident: 856_CR40 publication-title: Nat Med doi: 10.1038/s41591-018-0041-7 – volume: 4 start-page: e1027469 issue: 11 year: 2015 ident: 856_CR7 publication-title: Oncoimmunology doi: 10.1080/2162402X.2015.1027469 – ident: 856_CR43 doi: 10.1182/blood-2016-04-703751 – ident: 856_CR20 doi: 10.1056/NEJMoa1709919 – volume: 21 start-page: 2087 issue: 11 year: 2013 ident: 856_CR13 publication-title: Mol Ther doi: 10.1038/mt.2013.185 – volume: 13 start-page: 739 issue: 10 year: 2013 ident: 856_CR17 publication-title: Nat Rev Cancer doi: 10.1038/nrc3581 – volume: 121 start-page: 5154 issue: 26 year: 2013 ident: 856_CR38 publication-title: Blood doi: 10.1182/blood-2013-02-485623 – volume: 20 start-page: 506 issue: 4 year: 2018 ident: 856_CR14 publication-title: Neuro Oncol doi: 10.1093/neuonc/nox182 – volume: 11 start-page: 127 year: 2018 ident: 856_CR29 publication-title: Mol Ther Oncolytics doi: 10.1016/j.omto.2018.10.006 – volume: 124 start-page: 188 issue: 2 year: 2014 ident: 856_CR25 publication-title: Blood doi: 10.1182/blood-2014-05-552729 – ident: 856_CR19 doi: 10.1182/blood-2015-03-580027 – volume: 25 start-page: 625 issue: 4 year: 2019 ident: 856_CR26 publication-title: Biol Blood Marrow Transplant doi: 10.1016/j.bbmt.2018.12.758 – volume: 5 start-page: 1282 issue: 12 year: 2015 ident: 856_CR8 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-15-1020 – volume: 4 start-page: 498 issue: 6 year: 2016 ident: 856_CR30 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-15-0231 – volume: 33 start-page: 540 issue: 6 year: 2015 ident: 856_CR24 publication-title: J Clin Oncol doi: 10.1200/JCO.2014.56.2025 – volume: 3 start-page: 95ra73 issue: 95 year: 2011 ident: 856_CR23 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3002842 – volume: 8 start-page: 1219 issue: 10 year: 2018 ident: 856_CR28 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-18-0442 – ident: 856_CR6 doi: 10.1093/jnci/djv439 – volume: 120 start-page: 2032 issue: 10 year: 2012 ident: 856_CR22 publication-title: Blood doi: 10.1182/blood-2011-12-399287 – volume: 130 start-page: 3889 issue: Suppl. 1 year: 2017 ident: 856_CR32 publication-title: Blood – volume: 24 start-page: 739 issue: 6 year: 2018 ident: 856_CR41 publication-title: Nat Med doi: 10.1038/s41591-018-0036-4 – volume: 103 start-page: e215 issue: 5 year: 2018 ident: 856_CR35 publication-title: Haematologica doi: 10.3324/haematol.2017.183459 – volume: 2 start-page: e105 year: 2013 ident: 856_CR12 publication-title: Mol Ther Nucleic Acids doi: 10.1038/mtna.2013.32 – volume: 109 start-page: 944 issue: 3 year: 2007 ident: 856_CR21 publication-title: Blood doi: 10.1182/blood-2006-05-018192 – volume: 1 start-page: 26 issue: 1 year: 2013 ident: 856_CR33 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-13-0006 – ident: 856_CR1 doi: 10.1056/NEJMoa1709866 – volume: 24 start-page: 9 issue: 1 year: 2012 ident: 856_CR39 publication-title: Curr Opin Pediatr doi: 10.1097/MOP.0b013e32834ec9c1 – volume: 24 start-page: 20 issue: 1 year: 2018 ident: 856_CR11 publication-title: Nat Med doi: 10.1038/nm.4441 – volume: 6 start-page: 664 issue: 6 year: 2016 ident: 856_CR42 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-16-0040 – volume: 379 start-page: 64 issue: 1 year: 2018 ident: 856_CR2 publication-title: N Engl J Med doi: 10.1056/NEJMra1706169 – volume: 202 start-page: 907 issue: 7 year: 2005 ident: 856_CR16 publication-title: J Exp Med doi: 10.1084/jem.20050732 – volume: 371 start-page: 1507 issue: 16 year: 2014 ident: 856_CR5 publication-title: N Engl J Med doi: 10.1056/NEJMoa1407222 – volume: 135 start-page: 17 issue: 1 year: 2020 ident: 856_CR36 publication-title: Blood doi: 10.1182/blood.2019000017 – volume: 126 start-page: 3036 issue: 8 year: 2016 ident: 856_CR15 publication-title: J Clin Invest doi: 10.1172/JCI83416 – volume: 121 start-page: 1077 issue: 7 year: 2013 ident: 856_CR27 publication-title: Blood doi: 10.1182/blood-2012-08-234492 – volume: 126 start-page: 2123 issue: 6 year: 2016 ident: 856_CR18 publication-title: J Clin Invest doi: 10.1172/JCI85309 – reference: 32423426 - J Hematol Oncol. 2020 May 18;13(1):53 |
| SSID | ssj0061920 |
| Score | 2.6245937 |
| Snippet | Background
Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited... Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the... Background Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited... Abstract Background Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 30 |
| SubjectTerms | Acute lymphoblastic leukemia Adolescent Adult Adults Antigens Antigens, CD19 - immunology Autografts B-ALL Bispecific Blast cells Blood Body weight Bone marrow Cancer Research CAR CD19 CD19 antigen CD22 CD22 antigen Cell therapy Cerebrospinal fluid Chemotherapy Clinical trials Cytokines Cytolytic activity FDA approval Female Flow cytometry Hematology Humans Immunotherapy Immunotherapy, Adoptive - adverse effects Immunotherapy, Adoptive - methods Leukemia Lymphatic leukemia Lymphocytes Lymphocytes T Male Medicine Medicine & Public Health Neoplasm Recurrence, Local - immunology Neoplasm Recurrence, Local - therapy Neurotoxicity Oncology Patients Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - immunology Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - therapy Rapid Communication Remission Sialic Acid Binding Ig-like Lectin 2 - immunology T cells Tisagenlecleucel Treatment Outcome Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Open Access Full Text dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yiPgifls9NYLgg5ZLk2ybPO6uHj7oIXLCvYV8FZdbu8d2V9g_wf_ambRdryfqiw8tpZmWJDOZ_CaZmRDy0msr6iBVHkolchntJNfCwa1iDuYHOYk-5Zn9UJ2cqLMz_enSUV_oE9alB-467mgSuHe1DhHBRaWdstKxIL2SVvJYpjBfVunBmOp0MFoFbAiRUeVRW-CGYI6mEmKMMlejaShl6_9dJ1-alK46TF7ZNU2T0fFtcqtHkXTa1f4OuRabu-TGx36f_B75MVtgCCW6AdH59HN-SnGBvqWd3zf8kjrgEJ2_LTS1TYAHzinAV9qFY-3oqqYpM0dLcaGWYsTLRRsDBRJoyzod0rOjs_Rbav12E-lyB4KxcoDGoVJ0Gbfn8dvC3idfjt-dzt_n_aELuYehuMm5cIAiHNOK1UpHL1SsVSEAmMElgwi4ciV8yaKagCnCaguIwpXBAzRTgQfxgBw0qyY-IpSDcWkBISpmo6x5YWsN1lPtaiuLIGOVkWLggfF9RnI8GGNpkmWiStPxzQDfTOKbURl5vf_mosvH8VfqGbJ2T4m5tNMLkDDTS5j5l4Rl5DkKhukCU_cawUxLgH68VKrMyKtEgToBGuBtH9oA3YDZtUaUhyNKGMt-XDwIn-l1SWu40AAi9ISzjLzYF-OX6B_XxNUWacAyreDSGXnYyeq-0aCyMXSdZ6QaSfGoV8YlzeJryjReFRwQrMzIm0Hef1Xrz73--H_0-hNyk6fxKnMmDsnBZr2NT8l1_32zaNfP0mj_CUIiVIE priority: 102 providerName: Directory of Open Access Journals – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgQWgvvFkCCxgJiQNEm9huYh_bwooDrNCyoL1ZfgUqSrpqWqT-BP41M05SyPKQ4JAoqsdpPJ4Zf2N7xoQ8ccrwyguZ-kLyVAQzShW3cCszC-ODGAUX88y-Lo-O5OmpetsFhTX9bvd-STJa6qjWsjhoclzUS9HdQZxQpPIiuQTDncQDG47ffejtL3oEWR8e89t6gyEoZur_1R7_NCCd3yx5bsU0DkSH1_6vCdfJ1Q540nErKTfIhVDfJFfedEvrt8i3yQyjLnHnEJ2Oj9MTinP6DW23isO_UAudSqcvckVN7eGBMQqIl7YRXBu6qGhM5tFQnNulGCRz1gRPgQRYsIzn-mzoJL6WGrdeBTrfgCwtLAB4-Cg6D-vP4cvM3CbvD1-eTF-l3TkNqQPtXaWMWwAeFruikio4LkMlcw5YDi7hucfJLu6KLMgReC9ZZQCE2MI7QHPSM8_vkJ16UYe7hDLwRw2ASpmZICqWm0qBw1XZyojci1AmJO-7TrsuiTmepTHX0ZmRhW55rIHHOvJYy4Q829Y5a1N4_JV6ghKxpcT02_GHxfKj7rRZjzxztlI-IOItlZVG2MwLJ4URLBTwkkcoT7qNZd0aET0uAC2yQsoiIU8jBZoRaIAzXTQEsAETcg0o9weUoP5uWNzLrO7MT6MZV4A71IhlCXm8LcaauKWuDos10oAzW8KlErLXivi20WDlMdqdJaQcCP-AK8OSevYpJicvcwagVyTkea8CPz7rz1y_92_k98kui1ok0ozvk53Vch0ekMvu62rWLB9Gc_AdQUVYJA priority: 102 providerName: Springer Nature |
| Title | Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia |
| URI | https://link.springer.com/article/10.1186/s13045-020-00856-8 https://www.ncbi.nlm.nih.gov/pubmed/32245502 https://www.proquest.com/docview/2391289520 https://www.proquest.com/docview/2386278629 https://pubmed.ncbi.nlm.nih.gov/PMC7126394 https://doaj.org/article/5d2cbf9de005479b8a4b0d4c84a42e68 |
| Volume | 13 |
| WOSCitedRecordID | wos000523731800003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1756-8722 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061920 issn: 1756-8722 databaseCode: RBZ dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1756-8722 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061920 issn: 1756-8722 databaseCode: DOA dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1756-8722 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061920 issn: 1756-8722 databaseCode: M~E dateStart: 20080101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1756-8722 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061920 issn: 1756-8722 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1756-8722 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061920 issn: 1756-8722 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1756-8722 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061920 issn: 1756-8722 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLink Contemporary customDbUrl: eissn: 1756-8722 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061920 issn: 1756-8722 databaseCode: RSV dateStart: 20081201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdgQ4gXvgeBUYyExANESxw3cZ5QWzaBxKqqDFSeLMd2oKIkpWmR-ifwX3PnpBkZYi88JGrqS-SP8_l3Z98dIc91qqLccOGbWEQ-t6rvp1EGtyTIYH3gfatdnNn3yXgsZrN00hjcquZY5U4mOkFtSo028iMWpSBK0z4LXi9_-Jg1CndXmxQaV8k-ps1GPk9mrcKFukGwc5QR8VEV4ragjwoTIo3YF53FyMXs_1sy_7E0XTw2eWHv1C1JJ7f-tzG3yc0GjNJBzT13yBVb3CXXT5vt9nvk13COnph4moiOBlP_jKKdv6L18XGoE81goOnoTZhSVRj4wRgFFExrr64tLXPqAnxUFO29FB1nlpU1FEigM1Yu18-WDt1nqdKbtaWLLfBXmQGoh0rRhd18s9_n6j75eHJ8NnrrN7kbfA0zeu2zKAMwkgWpCHKRWh0Jm4swAnwHFzeRQQNYpOPAij5oNEGuAJhksdGA8IRhJjoge0VZ2IeEMtBRFQBNESjLcxaqPAUlLM9yxUPDbeKRcDeIUjeBzTG_xkI6BUfEsh54CQMv3cBL4ZGX7TvLOqzHpdRD5I2WEkNyuz_K1RfZzHDZN0xneWosouAkzYTiWWC4FlxxZmP4yFPkLFn7t7aCRQ5iQJAsFiL2yAtHgaIFGqBV4yEB3YBBujqUhx1KEAm6W7xjO9mIpEqe85xHnrXF-CYesytsuUEaUHATuFKPPKiZvW00SH70gGceSTrToNMr3ZJi_tUFLE9CBkCYe-TVbsKcV-vfvf7o8lY8JjeYm8rcD6JDsrdebewTck3_XM-rVc8JAncXPbI_PB5Ppj1nb4GnybvTyWd4mn749Bui4WhG |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3bbtMw1BoDAS_cL4HBjATiYURLHDdxHhBqO6ZN6yqEhtQ349gOVJS0NC2on8DP8I2c4yQdGWJve-AhVVSfWPHJudrnQshznaooN1z4JhaRz63q-GmUwU8SZKAfeMdqV2d2kAyHYjRK322QX00uDIZVNjLRCWoz1bhHvsuiFERp2mHBm9k3H7tG4elq00KjIosju_oBLlv5-nAPvu8LxvbfnvQP_LqrgK-B1hY-izJQk1mQiiAXqdWRsLkII7A84OImMrg1E-k4sKIDtnaQK1CZWWw02B7CMBPBvJfIZZDjCTp7yWjt4KEvEjSJOSLeLUM8hvTRQUPLJvZFS_m5HgF_a4I_VOHZMM0zZ7VOBe7f_N-Qd4vcqI1t2q244zbZsMUdcvW4Die4S372xphpitFStN99759QPMcoaRUeDzigGRAy7e-FKVWFgRvGKFj5tMpaW9FpTl0Bk5LifjbFxKBZaQ0FEED-3PUyWtGem5YqvVxYOlkB_0wzcFrgpejELr_Yr2N1j3y4EETcJ5vFtLAPCWXggyswpEWgLM9ZqPIUnMw8yxUPDbeJR8KGaKSuC7dj_5CJdA6ciGVFaBIITTpCk8IjO-tnZlXZknOhe0iLa0gsOe7-mM4_yVqCyY5hOstTY9HKT9JMKJ4FhmvBFWc2hkm2kZJllb-7FpyyG4OFzGIhYo-8dBAoOmEBWtUZIIAGLELWgtxqQYLI0-3hhsxlLXJLeUrjHnm2HsYnMYywsNMlwoADn8CVeuRBxVzrRYNmwwx_5pGkxXYtrLRHivFnV5A9CRkY-twjrxoGPX2tf2P90fmr2CbXDk6OB3JwODx6TK4zJ0a4H0RbZHMxX9on5Ir-vhiX86dOCFHy8aIZ9zdpvrte |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdgoIkXvgeBwYyExANESxw3sR_bjgrEqCYYaG-WYztQUZKqaZH6J_Bfc-ckZRkfEuIhVVWf0_hyd_6dfXcm5KmROiksF6FNRRJypwehTHL4yKIc5gc-cMbXmT3OplNxdiZPzmXx-2j3bkuyyWnAKk3l6nBhi0bFRXpYx7jBF6Lrg5ghDcVlcoVjID366-8_drYYvYOoS5X5bb_edOSr9v9qm89NThcDJy_snvpJaXLj_4dzk1xvASkdNhJ0i1xy5W2y-7bdcr9Dvo9mmI2JEUV0PHwXnlJc669pE0IO_0hzeNl0fBRLqksLXxijgIRpk9m1oVVBfZGPmuKaL8XkmUXtLAUSYMfSn_ezoSN_W6rNeuXofAMyVuUA7OGh6Nytv7ivM32XfJi8PB2_CtvzG0IDWr0KWZIDIMkjKaJCSGcS4QoRJ4Dx4OI2sbgIlpg0cmIAXk1UaAAneWoNoDxhmU32yE5Zle4-oQz8VA1gU0Ta8YLFupDgiBV5oXlsucsCEnevUZm2uDmesTFX3skRqWp4rIDHyvNYiYA83_ZZNKU9_ko9QunYUmJZbv9DtfykWi1XA8tMXkjrEAlnMhea55HlRnDNmUvhJgcoW6rJcd0aFzVMAUWyVIg0IM88BZoXGIDRbZYEsAELdfUo93uUYBZMv7mTX9WapVqxRAIekQMWBeTJthl7Yqhd6ao10oCTm8ElA3KvEfftoMH6YxY8C0jWU4QeV_ot5eyzL1qexQzAMA_Ii04dfj7Wn7n-4N_ID8juydFEHb-evnlIrjGvUDyMkn2ys1qu3SNy1XxbzerlY28lfgC3X2Ps |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bispecific+CAR-T+cells+targeting+both+CD19+and+CD22+for+therapy+of+adults+with+relapsed+or+refractory+B+cell+acute+lymphoblastic+leukemia&rft.jtitle=Journal+of+hematology+and+oncology&rft.au=Dai%2C+Hanren&rft.au=Wu%2C+Zhiqiang&rft.au=Jia%2C+Hejin&rft.au=Tong%2C+Chuan&rft.date=2020-04-03&rft.issn=1756-8722&rft.eissn=1756-8722&rft.volume=13&rft.issue=1&rft.spage=30&rft_id=info:doi/10.1186%2Fs13045-020-00856-8&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-8722&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-8722&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-8722&client=summon |